Selective cell death mediated by small conditional RNAs.
Cancer cells are characterized by genetic mutations that deregulate cell proliferation and suppress cell death. To arrest the uncontrolled replication of malignant cells, conventional chemotherapies systemically disrupt cell division, causing diverse and often severe side effects as a result of collateral damage to normal cells. Seeking to address this shortcoming, we pursue therapeutic regulation that is conditional, activating selectively in cancer cells. This functionality is achieved using small conditional RNAs that interact and change conformation to mechanically transduce between detection of a cancer mutation and activation of a therapeutic pathway. Here, we describe small conditional RNAs that undergo hybridization chain reactions (HCR) to induce cell death via an innate immune response if and only if a cognate mRNA cancer marker is detected within a cell. The sequences of the small conditional RNAs can be designed to accept different mRNA markers as inputs to HCR transduction, providing a programmable framework for selective killing of diverse cancer cells. In cultured human cancer cells (glioblastoma, prostate carcinoma, Ewing's sarcoma), HCR transduction mediates cell death with striking efficacy and selectivity, yielding a 20- to 100-fold reduction in population for cells containing a cognate marker, and no measurable reduction otherwise. Our results indicate that programmable mechanical transduction with small conditional RNAs represents a fundamental principle for exploring therapeutic conditional regulation in living cells.
Venkataraman
Suvir
S
Department of Bioengineering, California Institute of Technology, Pasadena, CA 91125, USA.
Dirks
Robert M
RM
Ueda
Christine T
CT
Pierce
Niles A
NA
D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000235:genetics; D002470:Cell Survival; D006801:Humans; D006824:Hybridization, Genetic; D007113:Immunity, Innate; D040542:Mechanotransduction, Cellular; D035683:MicroRNAs / Q000235:genetics / Q000627:therapeutic use*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014161:Transduction, Genetic; D014407:Tumor Cells, Cultured
D014408:Biomarkers, Tumor; D035683:MicroRNAs
Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):75-86
17449137
Small. 2005 Mar;1(3):284-99
17193445
Nat Rev Cancer. 2004 Mar;4(3):177-83
14993899
Cancer Res. 1996 Feb 15;56(4):728-32
8631004
Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15275-8
15492210
Cancer Res. 2005 Oct 1;65(19):8984-92
16204072
Pharmacol Ther. 1992;54(3):307-17
1465480
Virology. 1997 Sep 29;236(2):354-63
9325243
Nature. 2009 Jan 22;457(7228):396-404
19158785
N Engl J Med. 1984 Aug 30;311(9):584-5
6749231
Science. 1988 Apr 8;240(4849):210-3
3281258
EMBO Mol Med. 2010 May;2(5):146-58
20432502
Cell Death Differ. 2009 Aug;16(8):1093-107
19373242
Nature. 2009 Jan 22;457(7228):426-33
19158789
Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31
8052651
Cancer Res. 1996 Nov 1;56(21):5079-86
8895767
Oncogene. 2003 Jun 12;22(24):3721-33
12802279
Nat Biotechnol. 2002 Sep;20(9):895-900
12205508
Nat Nanotechnol. 2007 Aug;2(8):490-4
18654346
Nucleic Acids Res. 1994 Dec 11;22(24):5506-7
7816645
Genes Dev. 1999 Dec 15;13(24):3280-93
10617576
J Virol. 1993 Dec;67(12):7695-700
7693978
Endocr Relat Cancer. 2001 Jun;8(2):83-96
11397666
Mol Cell Biol. 1992 Nov;12(11):5238-48
1357546
J Biol Chem. 2001 Jul 6;276(27):24946-58
11337501
Oncogene. 2001 Sep 10;20(40):5747-54
11607824
Nature. 1998 Feb 19;391(6669):806-11
9486653
Nature. 2010 Apr 15;464(7291):1067-70
20305636
Nature. 2000 Aug 10;406(6796):605-8
10949296
Nat Nanotechnol. 2007 May;2(5):275-84
18654284
Biochimie. 2007 Jun-Jul;89(6-7):799-811
17451862
J Interferon Res. 1993 Oct;13(5):323-8
7905506
Cell. 2005 Sep 23;122(6):901-13
16179259
Science. 2005 Jun 3;308(5727):1424-8
15933191
Mol Cell Biol. 1987 Apr;7(4):1568-71
3600637
Mol Ther. 2005 Nov;12(5):969-75
16084774
Biochimie. 2002 Sep;84(9):925-44
12458085
J Biol Chem. 2006 Jul 28;281(30):21458-21468
16717090
Virology. 1990 May;176(1):106-13
2330670